Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 2, 2014, Pages 117-125

  Kumar, Janani ^a   Ward, Alister C ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Cytokine signaling; Epithelial; IL 6R; JAK STAT pathway; Ovarian cancer

Indexed keywords

ENZYME INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 11 RECEPTOR; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; JANUS KINASE 1 INHIBITOR; JANUS KINASE 2 INHIBITOR; LEPTIN RECEPTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; ONCOSTATIN M RECEPTOR; PROTEIN INHIBITOR; RECEPTOR ANTIBODY; STAT3 INHIBITOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION;

CYTOKINE SIGNALING; EPITHELIAL; IL-6R; JAK-STAT PATHWAY; OVARIAN CANCER;

FEMALE; HUMANS; INTERLEUKIN-6; JANUS KINASES; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84893108576     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.12.003     Document Type: Review

References (174)

1. NBOCC, National Breast and Ovarian Cancer Centre Global Cancer Facts and Figures 2011.
2. Lengyel E. Ovarian cancer development and metastasis. Am. J. Pathol. 2010, 177:1053-1064.
3. Chen V.W., Ruiz B., Killeen J.L., Cote T.R., Wu X.C., Correa C.N. Pathology and classification of ovarian tumors. Cancer 2003, 97:2631-2642.
4. Soslow R.A. Histologic subtypes of ovarian carcinoma: an overview. Int. J. Gynecol. Pathol. 2008, 27:161-174.
5. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 2001, 22:255-288.
6. Roth L.M. Recent advances in the pathology and classification of ovarian sex cord-stromal tumors. Int. J. Gynecol. Pathol. 2006, 25:199-215.
7. Kurian A.W., Balise R.R., McGuire V., Whittemore A.S. Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynecol. Oncol. 2005, 96:520-530.
8. Marquez R.T., Baggerly K.A., Patterson A.P., Liu J., Broaddus R., Frumovitz M., Atkinson E.N., Smith D.I., Hartmann L., Fishman D., Berchuck A., Whitaker R., Gershenson D.M., Mills G.B., Bast R.C., Lu K.H. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 2005, 11:6116-6126.
9. Bell D.A. Origins and molecular pathology of ovarian cancer. Mod. Pathol. 2005, 18(Suppl. 2):S19-S32.
10. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 2004, 351:2519-2529.
11. Breedlove G., Busenhart C. Screening and detection of ovarian cancer. J. Midwifery Womens Health 2005, 50:51-54.
12. Chien J.R., Aletti G., Bell D.A., Keeney G.L., Shridhar V., Hartmann L.C. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J. Cell. Biochem. 2007, 102:1117-1129.
13. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008, 9:1191-1197.
14. Spiekermann K., Biethahn S., Wilde S., Hiddemann W., Alves F. Constitutive activation of Stat transcription factors in acute myelogenous leukemia. Eur. J. Haematol. 2001, 67:63-71.
15. Auersperg N., Woo M.M., Gilks C.B. The origin of ovarian carcinomas: a developmental view. Gynecol. Oncol. 2008, 110:452-454.
16. Shield K., Ackland M.L., Ahmed N., Rice G.E. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol. Oncol. 2009, 113:143-148.
17. Shield K., Riley C., Quinn M.A., Rice G.E., Ackland M.L., Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J. Carcinog. 2007, 6:11.
18. Ponnusamy M.P., Batra S.K. Ovarian cancer: emerging concept on cancer stem cells. J. Ovarian Res. 2008, 1:4.
19. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
20. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.
21. Sica A., Schioppa T., Mantovani A., Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 2006, 42:717-727.
22. Lan C., Huang X., Lin S., Huang H., Cai Q., Wan T., Lu J., Liu J. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol. Cancer Res. Treat. 2013, 12:259-267.
23. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., Huang E., Finlayson E., Simeone D., Welling T.H., Chang A., Coukos G., Liu R., Zou W. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
24. Kusuda T., Shigemasa K., Arihiro K., Fujii T., Nagai N., Ohama K. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol. Rep. 2005, 13:1153-1158.
25. + IL-17-producing T cells in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15505-15510.
26. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu. Rev. Immunol. 2009, 27:485-517.
27. Chen L.L., Ye F., Lu W.G., Yu Y., Chen H.Z., Xie X. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J. Obstet. Gynaecol. Res. 2009, 35:212-218.
28. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., Krzysiek R., Knutson K.L., Daniel B., Zimmermann M.C., David O., Burow M., Gordon A., Dhurandhar N., Myers L., Berggren R., Hemminki A., Alvarez R.D., Emilie D., Curiel D.T., Chen L., Zou W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9:562-567.
29. Leonard W.J., Lin J.-X. Cytokine receptor signaling pathways. J. Allergy Clin. Immunol. 2000, 105:877-888.
30. Burke F., Relf M., Negus R., Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 1996, 8:578-585.
31. Nash M., Ferrandina G., Gordinier M., Loercher A., Freedman R. The role of cytokines in both the normal and malignant ovary. Endocr. Relat. Cancer 1999, 6:93-107.
32. O'Sullivan L.A., Liongue C., Lewis R.S., Stephenson S.E.M., Ward A.C. Cytokine receptor signaling through the Jak/Stat/Socs pathway in disease. Mol. Immunol. 2007, 44:2497-2506.
33. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
34. Kishimoto T. Interleukin-6: from basic science to medicine - 40years in immunology. Annu. Rev. Immunol. 2005, 23:1-21.
35. Machelon V., Emilie D., Lefevre A., Nome F., Durand-Gasselin I., Testart J. Interleukin-6 biosynthesis in human preovulatory follicles: some of its potential roles at ovulation. J. Clin. Endocrinol. Metab. 1994, 79:633-642.
36. Trouillas M., Saucourt C., Guillotin B., Gauthereau X., Taupin J.L., Moreau J.F., Boeuf H. The LIF cytokine: towards adulthood. Eur. Cytokine Netw. 2009, 20:51-62.
37. Morikawa Y. Oncostatin M in the development of the nervous system. Anat. Sci. Int. 2005, 80:53-59.
38. Liongue C., Wright C., Russell A.P., Ward A.C. Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. Int. J. Biochem. Cell Biol. 2009, 41:2372-2375.
39. Huang L., Li C. Leptin: a multifunctional hormone. Cell Res. 2000, 10:81-92.
40. Kamimura D., Ishihara K., Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 2003, 149:1-38.
41. Imada K., Leonard W.J. The JAK-STAT pathway. Mol. Immunol. 2000, 37:1-11.
42. Rawlings J.S., Rosler K.M., Harrison D.A. The JAK/STAT signaling pathway. J. Cell Sci. 2004, 117:1281-1283.
43. Yu H., Jove R. The Stats of cancer - new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
44. Levy D.E., Lee C. What does Stat3 do?. J. Clin. Invest. 2002, 109:1143-1148.
45. Dijkgraaf E.M., Welters M.J., Nortier J.W., van der Burg S.H., Kroep J.R. Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr. Pharm. Des. 2012, 18:3816-3827.
46. Hodge D.R., Hurt E.M., Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 2005, 41:2502-2512.
47. Ahmed N., Pansino F., Clyde R., Murthi P., Quinn M.A., Rice G.E., Agrez M.V., Mok S., Baker M.S. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 2002, 23:237-244.
48. Wang Y., Li L., Guo X., Jin X., Sun W., Zhang X., Xu R.C. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 2012, 59:228-236.
49. Wang Y., Niu X.L., Qu Y., Wu J., Zhu Y.Q., Sun W.J., Li L.Z. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010, 295:110-123.
50. Kim D.J., Chan K.S., Sano S., Digiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol. Carcinog. 2007, 46:725-731.
51. Wormald S., Hilton D.J. Inhibitors of cytokine signal transduction. J. Biol. Chem. 2004, 279:821-824.
52. Lauta V.M. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. Cytokine 2001, 16:79-86.
53. Bellone S., Watts K., Cane S., Palmieri M., Cannon M.J., Burnett A., Roman J.J., Pecorelli S., Santin A.D. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol. Oncol. 2005, 98:92-98.
54. Songur N., Kuru B., Kalkan F., Ozdilekcan C., Cakmak H., Hizel N. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004, 90:196-200.
55. Belluco C., Nitti D., Frantz M., Toppan P., Basso D., Plebani M., Lise M., Jessup J.M. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann. Surg. Oncol. 2000, 7:133-138.
56. Altundag O., Altundag K., Gunduz E. Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. J. Clin. Oncol. 2005, 23:1044-1045.
57. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., Hsieh C.Y. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527.
58. Garcia-Tunon I., Ricote M., Ruiz A., Fraile B., Paniagua R., Royuela M. IL-6, its receptors and its relationship with BCL-2 and BAX proteins in infiltrating and in situ human breast carcinoma. Histopathology 2005, 47:82-89.
59. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005, 65:10794-10800.
60. Schwartsburd P.M. Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev. 2003, 22:95-102.
61. Watson J.M., Sensintaffar J.L., Berek J.S., Martínez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990, 50:6959-6965.
62. Wu S., Rodabaugh K., Martinez-Maza O., Watson J., Silberstein D., Boyer C., Peters W., Weinberg J., Berek J., Bast R. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am. J. Obstet. Gynecol. 1992, 166:997-1007.
63. Alberti C., Pinciroli P., Valeri B., Ferri R., Ditto A., Umezawa K., Sensi M., Canevari S., Tomassetti A. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 2012, 31:4139-4149.
64. Colomiere M., Ward A.C., Riley C., Trenerry M.K., Cameron-Smith D., Findlay J., Ackland L., Ahmed N. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br. J. Cancer 2009, 100:134-144.
65. Lutgendorf S.K., Weinrib A.Z., Penedo F., Russell D., DeGeest K., Costanzo E.S., Henderson P.J., Sephton S.E., Rohleder N., Lucci J.A., Cole S., Sood A.K., Lubaroff D.M. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J. Clin. Oncol. 2008, 26:4820-4827.
66. Scambia G., Testa U., Benedetti Panici P., Foti E., Martucci R., Gadducci A., Perillo A., Facchini V., Peschle C., Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br. J. Cancer 1995, 71:354-356.
67. Berek J.S., Chung C., Kaldi K., Watson J.M., Knox R.M., Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 1991, 164:1038-1042. (discussion 1042-1033).
68. Stone R.L., Nick A.M., McNeish I.A., Balkwill F., Han H.D., Bottsford-Miller J., Rupairmoole R., Armaiz-Pena G.N., Pecot C.V., Coward J., Deavers M.T., Vasquez H.G., Urbauer D., Landen C.N., Hu W., Gershenson H., Matsuo K., Shahzad M.M., King E.R., Tekedereli I., Ozpolat B., Ahn E.H., Bond V.K., Wang R., Drew A.F., Gushiken F., Lamkin D., Collins K., DeGeest K., Lutgendorf S.K., Chiu W., Lopez-Berestein G., Afshar-Kharghan V., Sood A.K. Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 2012, 366:610-618.
69. Anglesio M.S., George J., Kulbe H., Friedlander M., Rischin D., Lemech C., Power J., Coward J., Cowin P.A., House C.M., Chakravarty P., Gorringe K.L., Campbell I.G., Australian Ovarian Cancer Study, Okamoto A., Birrer M.J., Huntsman D.G., de Fazio A., Kalloger S.E., Balkwill F., Gilks C.B., Bowtell D.D. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin. Cancer Res. 2011, 17:2538-2548.
70. Rath K.S., Funk H.M., Bowling M.C., Richards W.E., Drew A.F. Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am. J. Obstet. Gynecol. 2010, 203:230.e1-8.
71. Obata N.H., Tamakoshi K., Shibata K., Kikkawa F., Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res. 1997, 17:337-342.
72. Duan Z., Foster R., Bell D.A., Mahoney J., Wolak K., Vaidya A., Hampel C., Lee H., Seiden M.V. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancers. Clin. Cancer Res. 2006, 12:5055-5063.
73. Penson R.T., Kronish K., Duan Z., Feller A.J., Stark P., Cook S.E., Duska L.R., Fuller A.F., Goodman A.K., Nikrui N., MacNeill K.M., Matulonis U.A., Preffer F.I., Seiden M.V. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int. J. Gynecol. Cancer 2000, 10:33-41.
74. Duan Z., Feller A.J., Penson R.T., Chabner B.A., Seiden M.V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin. Cancer Res. 1999, 5:3445-3453.
75. Coward J., Kulbe H., Chakravarty P., Leader D., Vassileva V., Leinster D.A., Thompson R., Schioppa T., Nemeth J., Vermeulen J., Singh N., Avril N., Cummings J., Rexhepaj E., Jirstrom K., Gallagher W.M., Brennan D.J., McNeish I.A., Balkwill F.R. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 2011, 17:6083-6096.
76. Duluc D., Delneste Y., Tan F., Moles M.P., Grimaud L., Lenoir J., Preisser L., Anegon I., Catala L., Ifrah N., Descamps P., Gamelin E., Gascan H., Hebbar M., Jeannin P. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110:4319-4330.
77. + peripheral blood mononuclear cells and induce M2-type macrophage polarization. J. Biol. Chem. 2009, 284:34342-34354.
78. Takaishi K., Komohara Y., Tashiro H., Ohtake H., Nakagawa T., Katabuchi H., Takeya M. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 2010, 101:2128-2136.
79. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008, 66:1-9.
80. + regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18460-18465.
81. Kato T., Furumoto H., Ogura T., Onishi Y., Irahara M., Yamano S., Kamada M., Aono T. Expression of IL-17 mRNA in ovarian cancer. Biochem. Biophys. Res. Commun. 2001, 282:735-738.
82. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009, 206:1457-1464.
83. Alshamsan A. Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma. Immunopharmacol. Immunotoxicol. 2012, 34:465-469.
84. Kryczek I., Wei S., Zhu G., Myers L., Mottram P., Cheng P., Chen L., Coukos G., Zou W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007, 67:8900-8905.
85. Lo C.W., Chen M.W., Hsiao M., Wang S., Chen C.A., Hsiao S.M., Chang J.S., Lai T.C., Rose-John S., Kuo M.L., Wei L.H. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011, 71:424-434.
86. Dimitriadis E., Stoikos C., Tan Y.L., Salamonsen L.A. Interleukin 11 signaling components signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) regulate human endometrial stromal cell differentiation. Endocrinology 2006, 147:3809-3817.
87. Nandurkar H.H., Robb L., Begley C.G. The role of IL-11 in hematopoiesis as revealed by a targeted mutation of its receptor. Stem Cells 1998, 16(Suppl. 2):53-65.
88. Li T.M., Wu C.M., Huang H.C., Chou P.C., Fong Y.C., Tang C.H. Interleukin-11 increases cell motility and up-regulates intercellular adhesion molecule-1 expression in human chondrosarcoma cells. J. Cell. Biochem. 2012, 113:3353-3362.
89. Lay V., Yap J., Sonderegger S., Dimitriadis E. Interleukin 11 regulates endometrial cancer cell adhesion and migration via STAT3. Int. J. Oncol. 2012, 41:759-764.
90. Putoczki T.L., Thiem S., Loving A., Busuttil R.A., Wilson N.J., Ziegler P.K., Nguyen P.M., Preaudet A., Farid R., Edwards K.M., Boglev Y., Luwor R.B., Jarnicki A., Horst D., Boussioutas A., Heath J.K., Sieber O.M., Pleines I., Kile B.T., Nash A., Greten F.R., McKenzie B.S., Ernst M. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013, 24:257-271.
91. Campbell C.L., Guardiani R., Ollari C., Nelson B.E., Quesenberry P.J., Savarese T.M. Interleukin-11 receptor expression in primary ovarian carcinomas. Gynecol. Oncol. 2001, 80:121-127.
92. Wu S., Zhang Y., Xu L., Dai Y., Teng Y., Ma S., Ho S.H., Kim J.M., Yu S.S., Kim S., Song S. Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy. Support. Care Cancer 2012, 20:1875-1884.
93. Hilton D.J., Nicola N.A., Metcalf D. Specific binding of murine leukemia inhibitory factor to normal and leukemic monocytic cells. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5971-5975.
94. Stejskal D., Ruzicka V. Cardiotrophin-1. Review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2008, 152:9-19.
95. Dhingra K., Sahin A., Emami K., Hortobagyi G.N., Estrov Z. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res. Treat. 1998, 48:165-174.
96. Kellokumpu-Lehtinen P., Talpaz M., Harris D., Van Q., Kurzrock R., Estrov Z. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int. J. Cancer 1996, 66:515-519.
97. Savarese T.M., Campbell C.L., McQuain C., Mitchell K., Guardiani R., Quesenberry P.J., Nelson B.E. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. Cytokine 2002, 17:324-334.
98. Choi C.H., Choi J.J., Park Y.A., Lee Y.Y., Song S.Y., Sung C.O., Song T., Kim M.K., Kim T.J., Lee J.W., Kim H.J., Bae D.S., Kim B.G. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival. Br. J. Cancer 2012, 107:91-99.
99. Ye F., Hu Y., Lu W., Zhou C., Xie X. Expression of leukaemia inhibitory factor in epithelial ovarian carcinoma: correlation with clinical characteristics. Histopathology 2008, 53:224-228.
100. Jeannin P., Duluc D., Delneste Y. IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-gamma. Immunotherapy 2011, 3:23-26.
101. Dey G., Radhakrishnan A., Syed N., Thomas J.K., Nadig A., Srikumar K., Mathur P.P., Pandey A., Lin S.K., Raju R., Prasad T.S. Signaling network of oncostatin M pathway. J. Cell Commun. Signal. 2013, 7:103-108.
102. Gomez-Lechon M.J. Oncostatin M: signal transduction and biological activity. Life Sci. 1999, 65:2019-2030.
103. Douglas A.M., Goss G.A., Sutherland R.L., Hilton D.J., Berndt M.C., Nicola N.A., Begley C.G. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 1997, 14:661-669.
104. Ganapathi M.K., Weizer A.K., Borsellino S., Bukowski R.M., Ganapathi R., Rice T., Casey G., Kawamura K. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components. Cell Growth Differ. 1996, 7:923-929.
105. Mori S., Murakami-Mori K., Bonavida B. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. Anticancer Res. 1999, 19:1011-1015.
106. Li Q., Zhu J., Sun F., Liu L., Liu X., Yue Y. Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3. Int. J. Mol. Med. 2011, 28:101-108.
107. Watford W.T., Hissong B.D., Bream J.H., Kanno Y., Muul L., O'Shea J.J. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 2004, 202:139-156.
108. Del Vacchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., Anichini A. Interleukin 12: biological properties and clinical applications. Clin. Cancer Res. 2007, 13:4677-4685.
109. Wolf A.M., Rumpold H., Reimer D., Marth C., Zeimet A.G., Wolf D. High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer. Gynecol. Oncol. 2010, 118:244-250.
110. Bozkurt N., Yuce K., Basaran M., Gariboglu S., Kose F., Ayhan A. Correlation of serum and ascitic IL-12 levels with second-look laparotomy results and disease progression in advanced epithelial ovarian cancer patients. Int. J. Gynecol. Cancer 2006, 16:83-86.
111. Anwer K., Kelly F.J., Chu C., Fewell J.G., Lewis D., Alvarez R.D. Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol. Oncol. 2013, 131:169-173.
112. Zhao Q., Wang C., Zhu J., Wang L., Dong S., Zhang G., Tian J. RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study. J. Exp. Clin. Cancer Res. 2011, 30:26.
113. Kastelein R.A., Hunter C.A., Cua D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 2007, 25:221-242.
114. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., Basham B., McClanahan T., Kastelein R.A., Oft M. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465.
115. + regulatory T cells. Science 2009, 325:1142-1146.
116. Zhang Z., Zhou B., Zhang J., Chen Y., Lai T., Yan L., Liang A., Li Y., Wang Y., Chen Y., Zhang L., Xi M.R. Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer. Cancer Genet. Cytogenet. 2010, 196:146-152.
117. Touw I.P., van de Geijn G.J. Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders. Front. Biosci. 2007, 12:800-815.
118. Panopoulos A.D., Watowich S.S. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine 2008, 42:277-288.
119. Roberts A.W. G-CSF: a key regulator of neutrophil production, but that's not all!. Growth Factors 2005, 23:33-41.
120. Chakraborty A., White S.M., Lerner S.P. Granulocyte colony-stimulating factor receptor signals for β1-integrin expression and adhesion in bladder cancer. Urology 2004, 63:177-183.
121. Gutschalk C.M., Herold-Mende C.C., Fusenig N.E., Mueller M.M. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res. 2006, 66:8026-8036.
122. Westphal G., Niederberger E., Blum C., Wollman Y., Knoch T.A., Rebel W., Debus J., Friedrich E. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002, 88:150-159.
123. Brandstetter T., Ninci E., Falken U., Wagner E., Hess R., Bauknecht T. rhG-CSF affects genes involved in mitogen signalling and early gene expression in the ovarian cancer cell line HEY. Int. J. Cancer 1998, 75:847-854.
124. Ninci E.B., Brandstetter T., Meinhold-Heerlein I., Bettendorf H., Sellin D., Bauknecht T. G-CSF receptor expression in ovarian cancer. Int. J. Gynecol. Cancer 2000, 10:19-26.
125. Savarese T.M., Mitchell K., McQuain C., Campbell C.L., Guardiani R., Wuu J., Ollari C., Reale F., Nelson B.E., Chen A., Quesenberry P.J. Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett. 2001, 162:105-115.
126. Brandstetter T., Ninci E., Bettendorf H., Perewusnyk G., Stolte J., Herchenbach D., Sellin D., Wagner E., Kochli O.R., Bauknecht T. Granulocyte colony-stimulating factor (G-CSF) receptor gene expression of ovarian carcinoma does not correlate with G-CSF caused cell proliferation. Cancer 2001, 91:1372-1383.
127. Munstedt K., Hackethal A., Eskef K., Hrgovic I., Franke F.E. Prognostic relevance of granulocyte colony-stimulating factor in ovarian carcinomas. Arch. Gynecol. Obstet. 2010, 282:301-305.
128. Spinner D.M., Brandstetter T., Kiechle-Schwarz M., Du Bois A., Angel P., Bauknecht T. c-Jun expression and growth stimulation in human ovarian carcinoma cell lines following exposure to cytokines. Int. J. Cancer 1995, 63:423-427.
129. Kumar J., Fraser F.W., Riley C., Ahmed N., McCulloch D.R., Ward A.C. Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer. Br. J. Cancer 2014, (in press). 10.1038/bjc.2013.673.
130. Tartaglia L.A. The leptin receptor. J. Biol. Chem. 1997, 272:6093-6096.
131. Nakashima K., Narazaki M., Taga T. Leptin receptor (OB-R) oligomerizes with itself but not with its closely related cytokine signal transducer gp130. FEBS Lett. 1997, 403:79-82.
132. Villanueva E.C., Myers M.G. Leptin receptor signaling and the regulation of mammalian physiology. Int. J. Obes. (Lond.) 2008, 32(Suppl. 7):S8-S12.
133. Chua S.C., Koutras I.K., Han L., Liu S.M., Kay J., Young S.J., Chung W.K., Leibel R.L. Fine structure of the murine leptin receptor gene: splice site suppression is required to form two alternatively spliced transcripts. Genomics 1997, 15:264-270.
134. Somasundar P., Frankenberry K.A., Skinner H., Vedula G., McFadden D.W., Riggs D., Jackson B., Vangilder R., Hileman S.M., Vona-Davis L.C. Prostate cancer cell proliferation is influenced by leptin. J. Surg. Res. 2004, 118:71-82.
135. Saxena N.K., Sharma D., Ding X., Lin S., Marra F., Merlin D., Anania F.A. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67:2497-2507.
136. Saxena N.K., Vertino P.M., Anania F.A., Sharma D. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to Cyclin D1 promoter via activation of Stat3. J. Biol. Chem. 2007, 282:13316-13325.
137. Sharma D., Saxena N.K., Vertino P.M., Anania F.A. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr. Relat. Cancer 2006, 13:629-640.
138. Yin N., Wang D., Zhang H., Yi X., Sun X., Shi B., Wu H., Wu G., Wang X., Shang Y. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res. 2004, 64:5870-5875.
139. Hu X., Juneja S.C., Maihle N.J., Cleary M.P. Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J. Natl. Cancer Inst. 2002, 94:1704-1711.
140. Yan D., Avtanski D., Saxena N.K., Sharma D. Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires beta-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J. Biol. Chem. 2012, 287:8598-8612.
141. Wazir U., Al Sarakbi W., Jiang W.G., Mokbel K. Evidence of an autocrine role for leptin and leptin receptor in human breast cancer. Cancer Genomics Proteomics 2012, 9:383-387.
142. Hoda M.R., Theil G., Mohammed N., Fischer K., Fornara P. The adipocyte-derived hormone leptin has proliferative actions on androgen-resistant prostate cancer cells linking obesity to advanced stages of prostate cancer. J. Oncol. 2012, 2012:280-386.
143. Loffler S., Aust G., Kohler U., Spanel-Borowski K. Evidence of leptin expression in normal and polycystic human ovaries. Mol. Hum. Reprod. 2001, 7:1143-1149.
144. Uddin S., Bu R., Ahmed M., Abubaker J., Al-Dayel F., Bavi P., Al-Kuraya K.S. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol. Cancer 2009, 8:74.
145. Choi J.H., Park S.H., Leung P.C., Choi K.C. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J. Clin. Endocrinol. Metab. 2005, 90:207-210.
146. Ptak A., Kolaczkowska E., Gregoraszczuk E.L. Leptin stimulation of cell cycle and inhibition of apoptosis gene and protein expression in OVCAR-3 ovarian cancer cells. Endocrine 2013, 43:394-403.
147. Chen C., Chang Y.C., Lan M.S., Breslin M. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing Cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways. Int. J. Oncol. 2013, 42:1113-1119.
148. Choi J.H., Lee K.T., Leung P.C. Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth. Carcinogenesis 2011, 32:589-596.
149. Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 2003, 9:4653-4665.
150. Voorhees P.M., Chen Q., Kuhn D.J., Small G.W., Hunsucker S.A., Strader J.S., Corringham R.E., Zaki M.H., Nemeth J.A., Orlowski R.Z. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin. Cancer Res. 2007, 13:6469-6478.
151. Wallner L., Dai J., Escara-Wilke J., Zhang J., Yao Z., Lu Y., Trikha M., Nemeth J.A., Zaki M.H., Keller E.T. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res. 2006, 66:3087-3095.
152. Dorff T.B., Goldman B., Pinski J.K., Mack P.C., Lara P.N., Van Veldhuizen P.J., Quinn D.I., Vogelzang N.J., Thompson I.M., Hussain M.H. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin. Cancer Res. 2010, 16:3028-3034.
153. Puchalski T., Prabhakar U., Jiao Q., Berns B., Davis H.M. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 2010, 16:1652-1661.
154. Guo Y., Nemeth J., O'Brien C., Susa M., Liu X., Zhang Z., Choy E., Mankin H., Hornicek F., Duan Z. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin. Cancer Res. 2010, 16:5759-5769.
155. Garnero P., Thompson E., Woodworth T., Smolen J.S. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010, 62:33-43.
156. Minturn J.E., Evans A.E., Villablanca J.G., Yanik G.A., Park J.R., Shusterman S., Groshen S., Hellriegel E.T., Bensen-Kennedy D., Matthay K.K., Brodeur G.M., Maris J.M. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother. Pharmacol. 2011, 68:1057-1065.
157. Leah E. Clinical trials: phase III trial results for tofacitinib bring new oral DMARD therapy a step closer for patients with rheumatoid arthritis. Nat. Rev. Rheumatol. 2012, 8:561.
158. Younes A., Romaguera J., Fanale M., McLaughlin P., Hagemeister F., Copeland A., Neelapu S., Kwak L., Shah J., de Castro Faria S., Hart S., Wood J., Jayaraman R., Ethirajulu K., Zhu J. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J. Clin. Oncol. 2012, 30:4161-4167.
159. Schust J., Sperl B., Hollis A., Mayer T.U., Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 2006, 13:1235-1242.
160. Bid H.K., Oswald D., Li C., London C.A., Lin J., Houghton P.J. Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS One 2012, 7:e35513.
161. Kandala P.K., Srivastava S.K. Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo. Drug Discov. Ther. 2012, 6:94-101.
162. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., Buettner R., Proia D., Kowolik C.M., Xin H., Armstrong B., Bebernitz G., Weng S., Wang L., Ye M., McEachern K., Chen H., Morosini D., Bell K., Alimzhanov M., Ioannidis S., McCoon P., Cao Z.A., Yu H., Jove R., Zinda M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497.
163. Duan Z., Ames R.Y., Ryan M., Hornicek F.J., Mankin H., Seiden M.V. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother. Pharmacol. 2009, 63:681-689.
164. Saydmohammed M., Joseph D., Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J. Cell. Biochem. 2010, 110:447-456.
165. Cai L., Zhang G., Tong X., You Q., An Y., Wang Y., Guo L., Wang T., Zhu D., Zheng J. Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010, 148:73-80.
166. Lee E.S., Ko K.K., Joe Y.A., Kang S.G., Hong Y.K. Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. Oncol. Lett. 2011, 2:115-121.
167. Kiger A.A., Jones D.L., Schulz C., Rogers M.B., Fuller M.T. Stem cell self renewal specified by Jak-Stat activation in response to a support cell cue. Science 2001, 294:2542-2545.
168. Yahata Y., Shirakata Y., Tokumaru S., Yamasaki K., Sayama K., Hanakawa Y., Detmar M., Hashimoto K. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J. Biol. Chem. 2003, 278:40026-40031.
169. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., Dalton W., Jove R., Pardoll D., Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10:48-54.
170. Davis N.B., Ryan C.W., Stadler W.M., Vogelzang N.J. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU Int. 2005, 96:787-790.
171. Wei L.H., Baumann H., Tracy E., Wang Y., Hutson A., Rose-John S., Henderson B.W. Interleukin-6 trans signaling enhances photodynamic therapy by modulating cell cycling. Br. J. Cancer 2007, 97:1513-1522.
172. Ray-Coquard I., Paradiso D., Guastalla J.P., Leduc B., Guichard F., Martin C., Chauvenet L., Haddad-Guichard Z., Lepille D., Orfeuvre H., Gautier H., Castera D., Pujade-Lauraine E. Intensified dose of cyclophosphomide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer: a randomised study from the GINECO group. Br. J. Cancer 2007, 97:1200-1205.
173. Yamada Y., Tomonaga M., Fukuda H., Hanada S., Utsunomiya A., Tara M., Sano M., Ikeda S., Takatsuki K., Kozuru M., Araki K., Kawano F., Niimi M., Tobinai K., Hotta T., Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br. J. Haematol. 2001, 113:375-382.
174. Schmeler K.M., Vadhan-Raj S., Ramirez P.T., Apte S.M., Cohen L., Bassett R.L., Iyer R.B., Wolf J.K., Levenback C.L., Gershenson D.M., Freedman R.S. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol. Oncol. 2009, 113:210-215.